芸香宁碱抑制血管生成作用的研究

目的：研究芸香宁碱对血管生成的抑制作用,并研究其初步的作用机制。方法用人脐静脉内皮细胞（HUVEC）的生长、迁移实验及体内动物模型－鸡胚绒毛尿囊膜法（CAM 法）研究化合物的体内外抗血管生成作用;用酶联免疫吸附法检测芸香宁碱在非凋亡剂量时对肿瘤细胞培养上清液中 VEGF 蛋白分泌量的影响。结果芸香宁碱对血管内皮细胞具有优先抑制作用,对 HUVEC 的半数抑制剂量为（33．2±0．4）μmol·L －1,而对其他肿瘤细胞的 IC50值均大于这一数值;芸香宁碱在体外能够明显抑制内皮细胞的迁移和对细胞外基质黏附作用,并呈剂量依赖性,体内实验显示30μmol·L －1剂量浓度时显著抑制 CAM新生血管形成;芸香宁碱在15μmol·L －1和30μmol·L －1的浓度剂量时显著抑制人肝癌 HepG2细胞培养上清液中VEGF 蛋白的分泌,具有显著性差异。结论芸香宁碱在非凋亡浓度剂量具有抑制新生血管形成作用,其机制与抑制血管内皮细胞增殖以及抑制肿瘤细胞表达 VEGF 有关。     

新生霉素抑制血管生成及其与长春新碱的协同作用

目的研究新生霉素的抑制血管生成作用及其机制。方法以鸡胚尿囊膜模型测定对血管生成的作用，并分别用MTT法、明胶酶谱法等观察新生霉素对于内皮细胞和肺癌PG细胞的影响。结果新生霉素200 μg/egg对鸡胚尿囊膜血管生成的抑制率为68.7％，且呈浓度依赖性抑制内皮细胞的增殖、运动、MMP-2分泌以及管腔的形成；新生霉素和长春新碱对血管生成及PG细胞的增殖均有明显的协同作用。结论本研究首次确定新生霉素具有抑制血管生成活性,与长春新碱联合可增强对血管生成的抑制作用。     

Taspine isolated from Radix et Rhizoma Leonticis inhibits proliferation and migration of endothelial cells as well as chicken chorioallantoic membrane neovascularisation

The aim of the present study was to investigate an anti-angiogenic effect of taspine isolated from Radix et Rhizoma Leonticsi. Taspine was screened for the first time, using cell membrane chromatography (CMC). The anti-angiogeneic activity of taspine was tested by using the chicken chorioallantoic membrane (CAM) neovascularisation model in vivo and the HUVEC proliferation and migration models in vitro, respectively. The results showed that taspine could inhibit CAM angiogenesis significantly within the concentration range of 0.5-2 mug/egg, proliferation and migration of endothelial cells in a dose-dependent manner. The CAM histomorphology results indicated that taspine could inhibit blood vessels sprouts and proliferation of vascular endothelial cell. These findings suggest that taspine is a promising candidate for use as an angiogenesis inhibitor.     

Ganoderma Lucidum polysaccharide peptides protect kidney from renal ischemia reperfusion injury via counteracting oxidative stress

OBJECTIVE Ganoderma lucidum polysaccharide peptides(GLPP)have an anti-oxidant activity.The oxidative stress implicates in the pathogenesis of renal ischemia-reperfusion injury(RIRI).The objective of this study was to determine whether GLPP could attenuate RIRI via counteracting the oxidative stress.METHODS Mice subjected to uninephrectomy with the right kidney ischemia for 35 min and reperfusion for 24 hwere used to explore the protective activity of GLPP against RIRI.In GLPP-treated group,100mg·kg-1·d-1 of GLPP were intraperitoneally injected for 7dbefore the procedure.In vitro,NRK-52 Ecells subjected to hypoxia-reoxygenation(H/R)and tunicamycin were used to explore the protective effect of GLPP against oxidative stress.The mechanisms in which GLPP protected kidney from RIRI were studied using a series of physiological and molecular biological methods.RESULTS Kidneys undergone ischemia-reperfusion showed renal dysfunction and characteristic morphological changes including cellular necrosis,brush border loss,cast formation,vacuolization and tubular dilatation while these damages were significantly attenuated by GLPP treatment.The abnormal levels of MPO,MDA and SOD caused by renal ischemia-reperfusion were significantly reversed by GLPP treatment.More apoptotic cells were found in the renal ischemia-reperfusion group than the sham group whereas GLPP reduced apoptotic cells in the ischemia-reperfusion mice by21.75%(P<0.01).The GLPPs(25-1μg·mL)alleviated H/R induced cell viability loss by 20.12%(P<0.01)andΔφm dissipation by 27.3%(P<0.01)in vitro as well and its pretreatment dramatically reduced H/R and tunicamycin induced cell injury.CONCLUSION Our study found that GLPP had a protective effect on RIRI via its anti-oxidative capacity,which suggests that GLPP may be developed as a candidate drug for preventing acute kidney injury.     

Saikosaponins-b suppresses tumor growth and angiogenesis of hepatocellular carcinoma by regulating VEGF/ERK/HIF-1α signal pathway

OBJECTIVE Angiogenesis therapy has attracted interest as a potential treatment for hepatocellular carcinoma(HCC).In this study,we investigated the anti-proliferative activities and antiangiogenesis effects of saikosaponins(SS)-b on hepatocellular carcinoma(HCC)and its regulation on VEGF/ERK/HIF-1 αsignal pathway.METHODS H22 hepatoma-bearing mice model and HepG-2 cells were used to study the anti-tumor and anti-angiogenesis effects of SS-b in vivo and in vitro.Pathological change of tumor tissue was observed by HE staining,the microvascular changes were detected by immunohistochemical method.The effects of SS-b on angiogenesis were examined by using the chick embryo chorioallantoic membrane(CAM)model.The effects of SS-b on proliferation,migration and invasion were investigated by MTT assay,scratch wound healing assay and transwell assay inhuman umbilical vein endothelial cell(HUVEC)and HepG2 cells in vitro.Vascular endothelial growth factor(VEGF),matrix metalloproteinase-2/9(MMP-2/9),hypoxia-inducible factor-1α(HIF-1α)expression and the phosphorylation of extracellular regulated kinase(ERK)were analyzed using RT-PCR and Westernblot.RESULTS SS-b effectively inhibited the tumor growth of H22 mice in vivo.The inhibitory rate of tumor was 49.1%,50.7%,66.1%in SS-b 5,10 and 20 mg·kg-1group respectively.HE staining results showed that SS-b induced tumor necrosis and nuclear dissolution in H22 mice.Moreover,SS-b also reduced the number of microvessels of tumor tissue in H22 mice significantly and suppressed the angiogenesis of CAM induced by b-FGF.SS-b had an obvious inhibitory effect on cell proliferation,migration and invasion of HUVEC cells and HepG-2 cells.These effects were associated with downregulation of the expression of MMP2/9 and suppression of VEGF/ERK/HIF-1αsignaling in H22 mice and Hep-G2 cells.CONCLUSION Our findings showed that SS-b exerts anti-tumor effects by inhibiting tumor angiogenesis via regulating VEGF/ERK/HIF-1α signal pathway in vivo and in vitro.     

蝎毒多肽提取物抗肿瘤血管生成作用的实验研究

目的探讨东亚钳蝎蝎毒的多肽提取物PESV的抗血管生成活性和对肿瘤生长的抑制作用。方法①用不同浓度的PESV(4～20mg·L-1)作用于人脐静脉内皮细胞(HUVEC),采用BrdU参入的ELISA法观察HUVEC增殖活性和凋亡水平变化,流式细胞术检测凋亡细胞比例,免疫组化法检测Bal和Bax表达。②观察PESV对鸡胚尿囊膜(CAM)新生血管生成的影响。③皮下注射PESV(0.3mg·kg-1),观察对S180肉瘤和H22肝癌荷瘤小鼠肿瘤生长、肿瘤血管生成和血管生成因子(VEGF和bFGF)表达的影响。结果①体外实验显示,PESV在8～20mg·L-1范围明显抑制HUVEC的增殖活性(与对照组比较,P<0.01),而对乳腺癌细胞MDAMB231的增殖无影响;PESV作用后HUVEC凋亡细胞比例较对照组增加,P<0.05,Bax表达增加;Bcl2表达降低。②0.5mg/CAM和0.8mg/CAM的PESV能明显抑制CAM新生血管的形成。③体内实验显示PESV能明显抑制小鼠S180肉瘤和H22肝癌的肿瘤生长和血管生成水平,并降低肿瘤组织内血管生成相关因子VEGF和bFGF的表达。结论PESV具有良好的体内和体外抗肿瘤血管生成活性,并籍此抑制肿瘤的生长。     

鬼箭羽提取物抑制血管生成的实验研究

目的 研究鬼箭羽氯仿提取物对血管生成的影响.方法 采用人脐静脉内皮细胞模型（HUVEC）、大鼠动脉环模型（rat aortic rings）和鸡胚绒毛尿囊膜（CAM）模型研究鬼箭羽提取物抑制血管生成作用.结果 8μg·mL-1鬼箭羽提取物显著抑制人脐静脉内皮细胞的增殖,抑制率达到36.2%;2μg·mL-1和4μg·mL-1鬼箭羽提取物能够显著抑制大鼠动脉环新血管结构形成,抑制率分别达到56.41%和65.25%;鬼箭羽提取物20 μg·个-1与40μg·个-1.对鸡胚绒毛尿囊膜（CAM）血管抑制率分别达到了22.6%与31.2%.结论 鬼箭羽提取物具有显著的抗血管生成活性.     

槲皮素抑制血管生成作用的实验研究

目的　研究槲皮素 (Quercetin)对血管生成和培养的人脐静脉内皮细胞 (HUVEC)的影响。方法　采用生长因子 (血管内皮细胞生长因子VEGF、碱性成纤维细胞生长因子bFGF)诱导的鸡胚绒毛尿囊膜 (CAM)血管增生模型观察槲皮素对血管生成的影响 ;利用培养的HUVEC ,用MTT法观察槲皮素抑制内皮细胞增殖的作用 ;流式细胞仪观察槲皮素对HUVEC细胞周期的影响。结果　槲皮素 (0 1、0 0 5和 0 0 2 5mmol·L-1)能明显抑制VEGF诱导的CAM小血管生成 ;槲皮素 (0 1和 0 0 5mmol·L-1)能明显抑制bFGF诱导的CAM小血管生成 ;槲皮素 (2 4 0、12 0 μmol·L-1和 6 0 μmol·L-1)对内皮细胞增殖有抑制作用 ,抑制率分别为 6 7 0 %、5 8 1%和39 7% ;槲皮素 (2 4 0、12 0 μmol·L-1)能显著导致HUVEC的S、G2 期阻滞。结论　槲皮素能抑制VEGF和bFGF诱导的血管生成 ,且对内皮细胞增殖具有抑制作用。     

灵芝多糖肽对氧自由基损伤巨噬细胞的保护作用

目的:研究灵芝多糖肽(GLPP)在离体和整体水平对氧自由基(ROS)(tBOOH为氧化剂)损伤巨噬细胞的保护作用.方法:以tBOOH为氧化剂损伤小鼠腹腔巨噬细胞,以MTT法分析小鼠巨噬细胞存活率,在光镜和电子显微镜下观察细胞的形态改变.结果:GLPP50,100,200 mg/kg腹腔注射5天,能抑制巨噬细胞膜样变性和坏死,细胞存活率提高.在培养的巨噬细胞中加入 GLPP 3.125,12.5,50,200 mg/L,产生相似的保护作用.电镜观察发现,GLPP(100mg/kg)腹腔注射5天可保护细胞器如线粒体免受tBOOH的损伤.结论:GLPP有显著的清除氧自由基和抗氧化作用.     

Inhibitory effects of 9-(4-thio-beta-D-ribo-pentofuranosyl)guanine on tumor growth and angiogenesis

BACKGROUND: To find a nucleoside with anti-angiogenic activity, we tried to screen an active compound from our nucleoside library. MATERIALS AND METHODS: The compound inhibiting the growth of human umbilical vein endothelial cell (HUVEC) induced by the conditioned medium of lung carcinoma cell line PC-9 was screened. The antitumor activity of the compound was evaluated against murine sarcoma S-180 implanted onto chick embryo chorioallantoic membrane (CAM). RESULTS: 9-(4-Thio-beta-D-ribo-pentofuranosyl)guanine (4'-thioguanosine) was found to be a potent inhibitor of the growth of HUVEC. The growth of S-180 implanted onto CAM was also inhibited by 4'-thioguanosine whereas the in vitro growth of S-180 was not inhibited. The administration of 4'-thioguanosine in mice caused unexpected side effect which suggested neurotoxicity. CONCLUSIONS: Antitumor effect of 4'-thioguanosine on S-180 was suggested to be due to inhibition of tumor angiogenesis. Because of toxicity of 4'-thioguanosine in mice, further development of the derivatives which have lower toxicity is required.     

Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1

Artesunate (ART) is a semi-synthetic derivative of artemisinin extracted from the plant Artemisia annua is a safe and effective antimalarial drug. In the present investigation, ART was found also to inhibit angiogenesis in vivo and in vitro. The anti-angiogenic effect in vivo was evaluated in nude mice by means of human ovarian cancer HO-8910 implantation and immunohistochemical stainings for microvessel (CD(31)), vascular endothelial growth factor (VEGF) and VEGF receptor KDR/flk-1. Tumor growth was decreased and microvessel density was reduced following drug treatment with no apparent toxicity to the animals. ART also remarkably lowered VEGF expression on tumor cells and KDR/flk-1 expression on endothelial cells as well as tumor cells. The in vitro effect of ART was tested on models of angiogenesis, namely, proliferation, migration and tube formation of human umbilical vein endothelial cells (HUVEC). The results showed that ART significantly inhibited angiogenesis in a dose-dependent form in the range of 0.5 approximately 50 micromol/l. Additionally, the inhibitory effect of ART on HVUEC proliferation was stronger than that on Hela, JAR, HO-8910 cancer cells, NIH-3T3 fibroblast cells and human endometrial cells, indicating that ART was selectively against HUVEC. These findings and the known low toxicity of ART are clues that ART may be a promising angiogenesis inhibitor.     

Beta-eudesmol suppresses tumour growth through inhibition of tumour neovascularisation and tumour cell proliferation

In the present study, we investigated the potential anti-angiogenic mechanism and anti-tumour activity of beta-eudesmol using in vitro and in vivo experimental models. Proliferation of human umbilical vein endothelial cells (HUVEC) stimulated with vascular endothelial growth factor (VEGF, 30 ng/ml) and basic fibroblast growth factor (bFGF, 30 ng/ml) was significantly inhibited by beta-eudesmol (50-100 microM). Beta-eudesmol (100 microM) also blocked the phosphorylation of cAMP response element binding protein (CREB) induced by VEGF (30 ng/ml) in HUVEC. Beta-eudesmol (10-100 microM) inhibited proliferation of HeLa, SGC-7901, and BEL-7402 tumour cells in a time- and dose-dependent manner. Moreover, beta-eudesmol treatment (2.5-5 mg/kg) significantly inhibited growth of H(22) and S(180) mouse tumour in vivo. These results indicated that beta-eudesmol inhibited angiogenesis by suppressing CREB activation in growth factor signalling pathway. This is the first study to demonstrate that beta-eudesmol is an inhibitor of tumour growth.     

Inhibition of vascular endothelial growth factor (VEGF)-induced endothelial proliferation, arterial relaxation, vascular permeability and angiogenesis by dobesilate

Vascular endothelial growth factor (VEGF) is a key factor in angiogenesis and vascular permeability which is associated with many pathological processes. 2,5-hydroxybenzene sulfonate (DHBS; dobesilate) is a small molecule with anti-angiogenic activity that has been described as an inhibitor of fibroblast growth factors (FGF). The aim of the present study was to evaluate the effects of DHBS on VEGF-induced actions. The effects of DHBS were evaluated on VEGF-induced proliferation in human umbilical vein endothelial cells (HUVEC) and rat aorta relaxation, as well as on in vivo VEGF-induced skin vascular permeability and neovascularization in rats. DHBS at 50 and 100 μM concentration significantly inhibited the proliferation of HUVEC induced by VEGF (10 ng/ml), without significantly affecting HUVEC proliferation in the absence of VEGF. Rapid VEGF-induced activation of Akt in HUVEC was also prevented by DHBS (100 μM). Additionally, DHBS (2 μM) specifically inhibited the relaxation of rat aorta induced by VEGF (0.1 to 30 ng/ml), but not endothelium-dependent relaxation to acetylcholine (1 nM to 10 μM). The in vivo enhancement of vascular permeability caused by VEGF injection (50 μl at 10 ng/ml) in rat skin was also inhibited by DHBS co-administration (200 μM) (74.8±3.8% inhibition of dye extravasation). Administration of DHBS (200 mg/kg/day; i.p.) also reduced VEGF-induced angiogenesis in vivo. DHBS inhibits main responses elicited in vitro and in vivo by VEGF. As a dual antagonist of VEGF and FGF activities, DHBS could be of therapeutic interest in the treatment of diseases related to VEGF/FGF overproduction and excessive angiogenesis.     

灵芝多糖肽对ECV304细胞氧化损伤的保护作用

目的研究灵芝多糖肽对ECV304氧化损伤的保护作用。方法培养ECV304细胞,以叔丁基氢过氧化物(tBOOH)为氧化剂损伤细胞,造成氧化损伤模型,培养液中加入不同浓度灵芝多糖(12.5、25、50、100mg.L-1),以MTT法测细胞存活率;以光镜、电镜检测细胞形态学改变及线粒体损伤;用AnnexinV/PI双标记细胞,流式细胞检测细胞凋亡的百分率。结果灵芝多糖(12.5、25、50、100mg.L-1)可减少叔丁基氢过氧化物对ECV304的氧化损伤,MTT检测灵芝多糖给药组,ECV304细胞存活率增加。光镜下可见细胞损伤减少,电镜可见灵芝多糖(50mg.L-1,温育24h)减轻细胞器如线粒体氧化损伤,减少细胞凋亡。细胞流式检测表明:对照组、给药组、损伤组总凋亡百分率分别2.24%±0.43%、24%±6.4%(P<0.01)、82.1%±7.9%。结论灵芝多糖肽(GLPP)对ECV304细胞氧化损伤具有保护作用。     

Juice of eclipta prostrata inhibits cell migration in vitro and exhibits anti-angiogenic activity in vivo

BACKGROUND: The invasion of cancer cells is critical for metastasis. The effects of Eclipta prostrata, a Thai medicinal plant, on invasion, migration and adhesion of cancer cells were investigated and the anti-angiogenic activity in vivo was evaluated. MATERIALS AND METHODS: In vitro invasion and migration assays were performed in modified Boyden chambers. In vivo anti-angiogenic activity was determined using the chick chorioallantoic membrane (CAM) assay. RESULTS: E. prostrata juice inhibited cancer invasion and migration, without affecting cell adhesion. Cell migration was inhibited in a variety of cancer cell types and in endothelial cells, with IC50 values of 31-70 microg/ml, much lower than the IC50 values for cytotoxicity of 203-1,217 microg/ml for cancer cells and >4,000 microg/ml for endothelial cells. Fifty percent inhibition of angiogenesis by E. prostrata juice was observed at 200 microg/egg. CONCLUSION: E. prostrata juice inhibited cancer and endothelial cell migration in vitro and also showed in vivo anti-angiogenic activity.     

华蟾素对人胆管癌细胞QBC939抑制作用研究

目的观察华蟾素体内外对人胆囊癌QBC939细胞的抑制作用。方法常规培养细胞,24 h后随机分为空白对照组和华蟾素组6个剂量组,分别于3个时相采用MTT法检测华蟾素对人胆囊癌细胞增殖的抑制作用;建立QBC939细胞裸鼠异种移植瘤模型,随机分为阴性对照组、5-Fu阳性对照组及华蟾素3个剂量组,每日腹腔注射给药,观察荷瘤裸鼠的一般活动状况及进食量;12 d后处死裸鼠,剥瘤称重并计算抑瘤率;取血,ELISA法检测血清中细胞因子IL-6、TNF-α和sVCAM-1含量。结果华蟾素6个剂量组对QBC939细胞的增殖均具有抑制作用,与对照组比较差异有统计学意义,并且随着剂量的增加和时间的延长,抑制率也增加;华蟾素腹腔注射给药可改善荷瘤裸鼠的一般活动状况,增加进食量;抑制荷瘤裸鼠移植瘤的生长,与对照组比较差异有统计学意义;提高血清TNF-α水平,降低IL-6和sVCAM-1水平,差异均有统计学意义。结论华蟾素体内外均可抑制胆囊癌QBC939细胞的生长,其体内抑瘤作用机制可能与上调裸鼠血清TNF-α细胞因子水平,下调IL-6和sVCAM-1水平有关。     

Rb对HepG2肝癌细胞系增殖的影响

目的研究Rb基因及其产物对HepG2肝癌细胞系增殖的影响。方法转染pRb质粒进入HepG2肝癌细胞系,用MTT法检测转染前后细胞增殖的变化,并将转染pRb质粒的HepG2肝癌细胞接种在裸鼠皮下建立肝癌裸鼠种植瘤模型,观察转染pRb质粒前后裸鼠体内种植瘤生长的变化。结果转染pRb质粒的HepG2肝癌细胞与未转染pRb质粒者相比细胞增殖受到抑制。成功建立HepG2肝癌细胞裸鼠体内种植瘤模型,转染pRb质粒的HepG2肝癌细胞的裸鼠体内种植瘤生长受抑制。转染组种植瘤体积第4周(429.7±114.987)mm3,第5周(657.90±187.27)mm3,第6周(892.56±258.73)mm3。结论Rb在体内和体外均能抑制肝癌细胞的增殖。     

α-双炔失碳酯体内、外抑制血管生成(英文)

目的:研究雌激素受体部分拮抗剂α-双炔失碳酯(α-Ano)对体内、外肿瘤血管生成的抑制作用.方法:在C57BL/6小鼠中观察Lewis肺癌的生长情况,用免疫组织化学方法观察肿瘤微血管密度(MVD):在鸡胚绒毛膜尿囊膜(CAM)模型上观察药物对血管生成的影响;用台盼蓝排染法研究药物对人脐静脉内皮细胞(HUVEC)生长的作用;在体外观察了药物对HUVEC的由伤口引起的迁移和对胶原基质的粘附活性的影响;用荧光法间接测定一氧化氮(NO)水平.结果:α-Ano显著地抑制Lewis肺癌的MVD,同时抑制小鼠皮下接种的肿瘤生长,MVD的降低程度与肿瘤生长的抑制程度相关.α-ANO在CAM模型上也显示出对血管生成的抑制活性,抑制率达53％,17α-雌二醇对α-Ano抑制CAM血管生成的活性无明显拮抗作用;α-Ano对HUVEC的增殖和迁移活性有抑制作用,但对HUVEC对Ⅰ型胶原的粘附能力无明显影响.同时,α-Ano能够抑制HUVEC释放NO的水平,且具有时间和剂量依赖性.结论:α-Ano具有血管生成抑制活性,此作用是通过减少NO的释放,随后抑制内皮细胞的增殖和迁移而实现的.     

A new dimethyl ester bisphosphonate inhibits angiogenesis and growth of human epidermoid carcinoma xenograft in nude mice

Bisphosphonates are extensively used in the treatment of patients with metastasis-induced osteolysis. The major drawback in the efficacy of all bisphosphonates lies in their high hydrophilic nature, which results in poor membrane permeability and low availability for soft tissues. A reasonable approach to overcome these problems consists in masking one or more ionizable groups of bisphosphonates, notably by esterification of the hydroxyl functions. We have previously shown that the novel non-nitrogen-containing bisphosphonate BP7033 inhibited angiogenesis and growth of primary tumors in nude mice. The present study focuses on the dimethyl-esterified analog of this compound (Me-BP7033). In-vitro, Me-BP7033 inhibited proliferation of human carcinoma A431 cells as well as their invasive activity based on a transwell invasion assay. in-vivo, administration of Me-BP7033 (0.3 mg/kg) twice a week for 5 weeks inhibited the tumor growth of A431 cells xenografted in nude mice by 65%. Immunostaining of endothelial cells (ECs) in tumor sections revealed that Me-BP7033 inhibited the intratumor ECs density by 60%. The in-vivo anti-angiogenic properties of Me-BP7033 were also demonstrated in an in-vivo angiogenesis assay showing that Me-BP7033 reduced the vascular endothelial growth factor-stimulated infiltration of ECs in a Matrigel plug by 70%. In summary, we demonstrated for the first time that a diesterified bisphosphonate exhibited in vivo both anti-tumoral and anti-angiogenic activities with no apparent sign of toxic effects. These new diesterified compounds, which could display enhanced bioavailability and pharmacokinetics, thus represent interesting candidates for therapeutic applications such as cancer treatment.     

PI3Kα抑制剂BYL719抑制脐静脉血管内皮细胞增殖及血管生成的研究

目的 探讨PI3Kα抑制剂BYL719对人脐静脉血管内皮细胞(human umbilical vein endothelial cells,HUVEC)增殖与血管生成的影响。方法 采用MTT法测定BYL719对HUVEC活力的抑制作用;用流式细胞术检测BYL719对其细胞周期的影响;体外小管形成实验观察BYL719对血管生成的影响;western blot检测Akt、p-Akt、cyclinD1和CDK4蛋白表达水平的变化。结果 BYL719抑制了HUVEC中Akt的磷酸化水平;BYL719作用细胞后,HUVEC的细胞活力显著降低;BYL719能够通过下调cyclinD1和CDK4的表达而阻滞细胞于G1期,进而抑制HUVEC的增殖;HUVEC经BYL719处理后,体外小管形成能力受到显著抑制。结论 BYL719降低了HUVEC中Akt的磷酸化水平,能够抑制HUVEC的细胞增殖和血管生成。